ATE406444T1 - GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE - Google Patents

GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE

Info

Publication number
ATE406444T1
ATE406444T1 AT04076254T AT04076254T ATE406444T1 AT E406444 T1 ATE406444 T1 AT E406444T1 AT 04076254 T AT04076254 T AT 04076254T AT 04076254 T AT04076254 T AT 04076254T AT E406444 T1 ATE406444 T1 AT E406444T1
Authority
AT
Austria
Prior art keywords
disease
proteins
directed
alzheime
detection
Prior art date
Application number
AT04076254T
Other languages
German (de)
Inventor
La Monte Suzanne M De
Jack R Wands
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE406444T1 publication Critical patent/ATE406444T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/474—Pancreatic thread protein; Reg protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)

Abstract

The present invention is directed to recombinant hosts expressing proteins associated with Alzheimer's Disease, neuroectodermal tumors, maligant astrocytomas, and glioblastomas. This invention is specifically directed to the recombinant hosts and vectors which contain the genes coding for the neuronal thread proteins. This invention is also directed to substantially pure neural thread protein, immunodiagnostic and molecular diagnostic methods to detect the presence of neural thread proteins, and the use of nucleic acid sequences which code neural thread proteins in gene therapy.
AT04076254T 1993-04-20 1994-04-20 GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE ATE406444T1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US5055993A 1993-04-20 1993-04-20

Publications (1)

Publication Number Publication Date
ATE406444T1 true ATE406444T1 (en) 2008-09-15

Family

ID=21965952

Family Applications (2)

Application Number Title Priority Date Filing Date
AT04076254T ATE406444T1 (en) 1993-04-20 1994-04-20 GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE
AT94915396T ATE312348T1 (en) 1993-04-20 1994-04-20 GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT94915396T ATE312348T1 (en) 1993-04-20 1994-04-20 GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE

Country Status (11)

Country Link
EP (2) EP0697893B1 (en)
JP (2) JP3513859B2 (en)
KR (1) KR100392244B1 (en)
AT (2) ATE406444T1 (en)
CA (1) CA2161097A1 (en)
DE (2) DE69435136D1 (en)
DK (2) DK0697893T3 (en)
ES (2) ES2255054T3 (en)
NZ (1) NZ266072A (en)
PT (1) PT1564293E (en)
WO (1) WO1994023756A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804560A (en) * 1995-01-06 1998-09-08 Sibia Neurosciences, Inc. Peptide and peptide analog protease inhibitors
US5936078A (en) * 1995-12-12 1999-08-10 Kyowa Hakko Kogyo Co., Ltd. DNA and protein for the diagnosis and treatment of Alzheimer's disease
AU1110297A (en) * 1995-12-12 1997-07-03 Kyowa Hakko Kogyo Co. Ltd. Novel dnas, novel polypeptides and novel antibodies
EP0975651A4 (en) 1997-02-26 2005-03-09 Gen Hospital Corp Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of alzheimer's disease
US7226730B1 (en) 1997-02-26 2007-06-05 The General Hospital Corporation Transgenic animals and cell lines for screening drugs effective for the treatment or prevention of Alzheimer's Disease
EP1006794B1 (en) 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
EP1541166B1 (en) * 2001-05-16 2007-12-19 Nymox Corporation Preventing cell death using segments of neural thread proteins
EP1392347B1 (en) * 2001-05-16 2005-08-03 Nymox Corporation Preventing cell death using segments of neural thread proteins
US6770797B2 (en) 2001-06-01 2004-08-03 Rhode Island Hospital Non-Transgenic nonhuman model for Alzheimer's Disease using a AD7c-NTP nucleic acid
EP1714979A3 (en) * 2001-11-16 2007-04-25 Nymox Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US7317077B2 (en) 2001-11-16 2008-01-08 Nymox Pharmaceutical Corporation Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
DK1994152T3 (en) 2006-02-28 2013-03-11 Nymox Corp PEPTIDES EFFECTIVE IN TREATMENT OF TUMORS AND OTHER CONDITIONS REQUIRING CELL REMOVAL OR DESTRUCTION
US20080027005A1 (en) * 2006-07-31 2008-01-31 Paul Averback Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
US11628202B2 (en) 2015-07-24 2023-04-18 Nymox Corporation Methods of reducing the need for surgery in patients suffering from benign prostatic hyperplasia
US10183058B2 (en) 2016-06-17 2019-01-22 Nymox Corporation Method of preventing or reducing the progression of prostate cancer
US10172910B2 (en) 2016-07-28 2019-01-08 Nymox Corporation Method of preventing or reducing the incidence of acute urinary retention
US10532081B2 (en) 2016-09-07 2020-01-14 Nymox Corporation Method of ameliorating or preventing the worsening or the progression of symptoms of BPH
US10335453B2 (en) 2017-03-01 2019-07-02 Nymox Corporation Compositions and methods for improving sexual function
WO2023217890A1 (en) * 2022-05-10 2023-11-16 F. Hoffmann-La Roche Ag Antisense oligonucleotides targeting cfp-elk1 intergene region

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3309972B2 (en) * 1988-12-21 2002-07-29 ザ・ジェネラル・ホスピタル・コーポレイション Methods for detecting nervous system disorders or dysfunction

Also Published As

Publication number Publication date
EP0697893A4 (en) 1996-12-18
CA2161097A1 (en) 1994-10-27
DE69434844T2 (en) 2006-12-14
DE69434844D1 (en) 2006-10-19
NZ266072A (en) 1997-07-27
JP2004097227A (en) 2004-04-02
JPH08509808A (en) 1996-10-15
DK0697893T3 (en) 2006-02-20
ES2255054T3 (en) 2006-06-16
AU6666994A (en) 1994-11-08
PT1564293E (en) 2008-12-02
EP1564293B9 (en) 2009-08-19
AU674581B2 (en) 1997-01-02
WO1994023756A1 (en) 1994-10-27
KR100392244B1 (en) 2003-11-28
ATE312348T1 (en) 2005-12-15
EP0697893A1 (en) 1996-02-28
EP1564293A1 (en) 2005-08-17
EP1564293B1 (en) 2008-08-27
JP3513859B2 (en) 2004-03-31
ES2312913T3 (en) 2009-03-01
DK1564293T3 (en) 2009-01-12
DE69435136D1 (en) 2008-10-09
EP0697893B1 (en) 2005-12-07

Similar Documents

Publication Publication Date Title
ATE406444T1 (en) GENE EXPRESSION OF NEUROFILAMENT PROTEINS AND DETECTION OF ALZHEIME'S DISEASE
EP0442961A4 (en) Hybrid procoagulant proteins
PT939804E (en) ALPHA NEUTROQUIN
SE8106641L (en) HYBRID HUMAN LEUKOCYTIN INTERFERONES
DE69735375D1 (en) GENE FAMILY OF APOPTOSIS-RELATED PEPTIDES, THEREFORE, ENCODED PEPTIDES AND METHOD FOR THE PRODUCTION THEREOF
DE3786200D1 (en) DIAGNOSTIC PROCEDURE FOR DETECTING LYMPHOMAS IN HUMANS.
ATE231551T1 (en) HUNTINGTIN DNA, PROTEIN AND USES
DE3684295D1 (en) ANTIGEN PROTEINS AND VACCINES CONTAINING THEM FOR THE PREVENTION OF COCCIDIOSIS.
ATE301716T1 (en) VMP-LIKE SEQUENCES OF PATHOGENIC BORRELIA
ATE365744T1 (en) NUCLEIC ACID MOLECULES, PROTEINS AND PEPTIDES ASSOCIATED WITH COLON CELLS AND COLON CANCER CELLS
DE69434926D1 (en) HUMAN TISSUE INHIBITOR OF METALOPROTEINASE-4
DE69635207D1 (en) Genome located on chromosome 1 whose gene product is associated with Alzheimer's disease.
DK1015477T3 (en) 32 human secreted proteins
NO177863C (en) Method for Preparation of Recombinant Human IFN Type I, IFN1, IFN-Pseudo-2, -3, and -4, and Expression Vectors
KR860006484A (en) Method for preparing protein or glycoprotein
ATE187202T1 (en) NUCLEOTIDE SEQUENCES ENCODING CRYPTOSPORIDIUM PROTEINS, POLYPEPTIDES ENCODED BY THESE SEQUENCES, AND KITS FOR USE THEREOF
AU5315790A (en) Molecules containing at least one peptide sequence carrying one or several epitopes characteristic of a protein produced by p. falciparum at the sporozoite stage and in the hepatocytes
NO962596L (en) New tumor suppressor gene
ATE300554T1 (en) CONNECTIVE TISSUE GROWTH FACTOR 3.
ZA200207883B (en) The High Bone Mass Gene of 11Q13.3.
ATE312914T1 (en) RDGB PROTEINS
Schröder et al. Identification of a novel platelet-derived neutrophil-chemotactic polypeptide with structural homology to platelet-factor 4
DE69033553D1 (en) RECOMBINANT PRODUCTION OF LACTOPEROXIDASE
EP0839910A3 (en) Spo-rel, a Staphylococcus relA/spot homologue
MX9801603A (en) Genetic alterations related to familial alzheimer's disease.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1564293

Country of ref document: EP

REN Ceased due to non-payment of the annual fee